Table 1.
Baseline Characteristics of Study Participants
| Variable | Spironolactone (n=29) | Placebo (n=32) | P-Value |
|---|---|---|---|
| Age, y | 34±10 | 34±9 | 0.9 |
| Male sex | 55% | 38% | 0.2 |
| Non-Hispanic White | 79% | 88% | 0.4 |
| BMI, kg/m2 | 27.2±4.7 | 27.1±5.3 | 0.9 |
| SBP, mmHg | 122±13 | 120±12 | 0.5 |
| DBP, mmHg | 79±9 | 76±11 | 0.2 |
| eGFR, ml/min/1.73m2 | 96±23 | 93±19 | 0.6 |
| LDL, mg/dL | 95±30 | 95±26 | 0.9 |
| HDL, mg/dL | 47±11 | 51±14 | 0.2 |
| Total Cholesterol, mg/dL | 162±36 | 167±29 | 0.5 |
| ACEi/ARB, % | 100% | 100% | 0.9 |
| Diuretic, % | 17% | 19% | 0.9 |
| CCB, % | 3% | 6% | 0.6 |
| Statin, % | 31% | 16% | 0.2 |
Continuous data expressed as mean±S.D. BMI, body-mass index; SBP, systolic blood pressure; SBP, systolic blood pressure, eGFR; estimated glomerular filtration rate; LDL, low density lipoprotein, HDL, high density lipoprotein; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. P-values are a comparison of the spironolactone and placebo groups using an independent samples t-test, chi-square test, or Fisher’s exact test.